Epigral

Sales down 7%, net down 62%

'Consolidated net sales (including other operating income) of Epigral has declined 7.46% to Rs 597.12 crore. Sequential fall in EBITDA margin stood at 17% vs 23% in Q2FY26 on account of drop in realizations and increase in cost of raw materials.

Operating profit margin has declined from 28.29% to 17.21%, leading to 43.71% decline in operating profit to Rs 102.74 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 51.29% to 63.37%. Employee cost increased from 4.53% to 4.84%. Other expenses rose from 15.73% to 16.04%. Power and Oil fuel cost rose from 4.80% to 6.49%.

Other income rose 44.04% to Rs 5.56 crore. PBIDT fell 41.89% to Rs 108.3 crore. PBDT fell 47.78% to Rs 97.35 crore. Provision for depreciation rose 29.90% to Rs 42.75 crore. Profit before tax down 64.44% to Rs 54.60 crore. Provision for tax was expe...

Pleaselogin & subscribe to view the full report.

More Reports

(31-Jan-2026)
New India Assurance Company
Net profit up 2.5% in Q3FY2026
(31-Jan-2026)
Jupiter Life Line Hospitals
NP down 18.31%
(31-Jan-2026)
Container Corporation Of India
Net down 9% despite 11% growth at OP
(31-Jan-2026)
Cholamandalam Investment & Finance Company
AUM growth at 20%

More Reports View Company Information

Results-Analysis (31-Jan-2026)
Epigral
Sales down 7%, net down 62%
Analyst Meet / AGM-Conference Call (31-Jan-2026)
Epigral
Q4FY26 will be better than Q3FY26
Analyst Meet / AGM-Conference Call (11-Nov-2025)
Epigral
Expects H2 performance to be better than H1
Results-Analysis (10-Nov-2025)
Epigral
Revenue 6% in H1FY26 on account of drop in sales volume

Tweets by CapitalMarket17

Epigral

LOGIN HERE